Printed From:

MEDICARE PATIENTS: CHECK TO MAKE SURE YOU’RE COVERED NEXT YEAR. LEARN MORE SAUS.SQA.19.10.5213 | 10/19

SOLIQUA 100/33 works 5 ways in your body

SOLIQUA 100/33 works 5 ways to deliver blood sugar control and help lower A1c.

SOLIQUA 100/33 works 5 ways to help deliver blood control sugar and lower your A1 illustration
  1. Bloodstream Helps reduce sugar buildup in your bloodstream
  2. Stomach Slows down the process by which sugar enters your bloodstream after eating
  3. Liver Helps slow down the processes by which the liver releases sugar into the bloodstream
  4. Pancreas Helps your pancreas release more insulin to help maintain lower blood sugar levels
  5. Muscles Helps muscles store glucose that your body doesn’t need right away so it can be used for energy later

Should you switch to SOLIQUA 100/33? Ask your doctor.

For patients not at goal on oral diabetes medication, SOLIQUA 100/33 was proven to lower A1c below 7%

In a clinical study, 74% of patients using SOLIQUA 100/33 lowered their A1c below 7%, while 59% of patients on Lantus® and 33% of patients on lixisenatide reached an A1c below 7%. On average, A1c was reduced from a starting point of 8.1% to 6.5% in patients taking SOLIQUA 100/33, from 8.1% to 6.8% in patients taking Lantus®, and from 8.1% to 7.3% in patients taking lixisenatide.

Your doctor may prescribe a dose of insulin that is different from the doses used in the study. The results seen in the trial may not reflect your results.

Individual results may vary.

The clinical study showed that in patients treated with metformin, SOLIQUA 100/33 improved blood sugar control compared to the individual components of SOLIQUA 100/33, a long-acting insulin (Lantus®), and non-insulin diabetes medicine (lixisenatide). The study included 1,479 patients with type 2 diabetes who had been taking oral diabetes medications and whose A1c was not at goal. After 4 weeks of taking metformin alone, 1,170 patients who had still not achieved their A1c goal (A1c 7-10%) and had a fasting blood sugar ≤250mg/dL continued in the study. For the next 30 weeks patients continued taking metformin and were also treated with SOLIQUA 100/33 (469 patients), Lantus® (467 patients), or lixisenatide (234 patients). Patients received insulin glargine 100 units/mL at a dose of 60 units or less in both Lantus® and SOLIQUA 100/33 groups. The study showed that combining lixisenatide with Lantus® in SOLIQUA 100/33 can help lower blood sugar even further in patients taking metformin.

2X Almost twice the A1c REDUCTION

For patients prescribed long-acting insulin, SOLIQUA 100/33 was proven to lower A1c below 7%

In a different clinical study, more than half (55%) of patients using SOLIQUA 100/33 lowered their A1c below 7%, versus 30% of patients using Lantus® reached an A1c below 7%. On average, A1c was reduced from a starting point of 8.1% to 6.9% in patients taking SOLIQUA 100/33 and 8.1% to 7.5% in Lantus® patients. Patients using SOLIQUA 100/33 achieved almost twice (-1.1% vs -0.6%) the A1c reduction than patients who were using Lantus®.§

Your doctor may prescribe a dose of insulin that is different from the doses used in the study. The differences between Lantus® and SOLIQUA 100/33 seen in the trial may not reflect your results.

Individual results may vary.

§The clinical study showed how adding a non-insulin diabetes medicine (lixisenatide) to Lantus®, a long-acting insulin, in a single injection improves blood sugar control. The study involved 1,018 patients with type 2 diabetes who had been taking a long-acting insulin for 6 or more months, but had still not reached their A1c goal. After 6 weeks of taking Lantus® at a dose of 50 units or less daily, 736 patients who had still not achieved their A1c goal and had a fasting blood sugar ≤140 mg/mL continued in the study. For the next 30 weeks, half of the patients continued on SOLIQUA 100/33 (Lantus® + non-insulin medicine) and half received Lantus®. The study showed that combining lixisenatide with Lantus® may help to lower blood sugar even further.


What you should know about the most common possible side effects of SOLIQUA 100/33

The most common side effects of SOLIQUA 100/33 may include low blood sugar (hypoglycemia), nausea, stuffy or runny nose and sore throat, diarrhea, upper respiratory tract infection, and headache. These are not all the possible side effects of SOLIQUA 100/33. Talk with your doctor about possible other side effects.

Nausea and diarrhea usually happen more often when you start using SOLIQUA 100/33.

SOLIQUA 100/33 delivers blood sugar control through the day and night clock icon

Helps manage blood sugar all day and night

SOLIQUA 100/33 delivers blood sugar control throughout the day and night.